Praxis Precision Medicines, Inc. Share Price
NASDAQ: PRAX | Mid CapPraxis Precision Medicines, Inc. Stock Performance
Open $377.46 | Prev. Close $370.88 | Circuit Range N/A |
Day Range $348.07 - $377.46 | Year Range $37.60 - $377.46 | Volume 29,686 |
Average Traded $355.72 |
Praxis Precision Medicines, Inc. Share Price Today
As of 10 August 2026, Praxis Precision Medicines, Inc.'s share price is $360.80. The stock opened at $377.46, compared to its previous close of $370.88. During today's trading session, Praxis Precision Medicines, Inc.'s share price traded between $348.07 and $377.46, with an average price of $362.76. Over the past 52 weeks, the stock has recorded a high of $377.46 and a low of $37.60. In terms of performance, Praxis Precision Medicines, Inc.'s share price has risen by 7.14% over the last six months and is up 693.49% on a year-on-year basis.
Praxis Precision Medicines, Inc. Share Price Chart
Praxis Precision Medicines, Inc. Stock Fundamentals & Key Indicators
Market Cap $8.12B | PE Ratio (TTM) -26.77 | Dividend Yield N/A |
EPS (TTM) $-13.48 | Revenue (TTM) N/A | Return On Equity (TTM) -34.54% |
Profit Margin N/A | Debt to Equity 0.07 | Quarterly Earnings Growth YoY -42.43% |
Praxis Precision Medicines, Inc. Quarterly Profit & Loss
All figures in USD
Praxis Precision Medicines, Inc. Annual Profit & Loss
All figures in USD
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050. In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
Praxis Precision Medicines, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $298.05 | $360.38 | +17.16% |
Jul 2026 | $333.60 | $307.61 | -8.22% |
Jun 2026 | $341.35 | $335.16 | -4.61% |
May 2026 | $313.27 | $351.36 | +9.82% |
Apr 2026 | $326.49 | $319.93 | -0.66% |
Mar 2026 | $330.00 | $322.05 | -4.36% |
Feb 2026 | $312.91 | $336.74 | +7.15% |
Jan 2026 | $291.22 | $314.26 | +6.45% |
Dec 2025 | $193.81 | $295.22 | +50.32% |
Nov 2025 | $183.11 | $196.40 | -1.15% |
Oct 2025 | $53.72 | $198.69 | +274.67% |
Sep 2025 | $45.75 | $53.03 | +16.63% |
PRAX Share Price FAQs
What is Praxis Precision Medicines, Inc. share price today?
What is the 52 week high and 52 week low of Praxis Precision Medicines, Inc. stock?
What is PRAX's market capitalisation today?
What is PRAX's net income for the last quarter?
What is the 5 year returns of PRAX?
What is the high & low stock price of PRAX today?
Can I buy PRAX shares in India?